Futura Medical launches DermaSys brand

5 March 2007

The UK's Futura Medical has launched DermaSys as the brand name for its versatile gel technology for the rapid delivery of drugs through the skin.

The platform was originally developed by Futura for use in its topical treatment for erectile dysfunction, MED2002. Futura is continuing its assessment program for DermaSys against a wide range of generic drugs suited to topical delivery where substantial improvements in speed of absorption and permeability across the skin would result in attractive commercial opportunities.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight